お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、糖尿病治療薬SGLT-2阻害剤の世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に糖尿病治療薬SGLT-2阻害剤市場を分類しています。
本レポートでは世界の糖尿病治療薬SGLT-2阻害剤市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Pfizer、AstraZeneca、Johnson & Johnson、GlaxoSmithKline、Merck & Co、Eli Lilly、Sanofi、Takeda Pharmaceuticals、Novo Nordisk、Servier Laboratories、Boehringer Ingelheim、Bristol-Myers Squibb

レポートは糖尿病治療薬SGLT-2阻害剤の主要生産者を調査し、主要地域や国の消費状況も提供します。糖尿病治療薬SGLT-2阻害剤の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Canagliflozin
    Empagliflozin
    Dapagliflozin
    Other

用途別の市場セグメント：
    Hospitals
    Clinics
    Other

本レポートの詳細内容
本レポートは、世界の糖尿病治療薬SGLT-2阻害剤市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて糖尿病治療薬SGLT-2阻害剤市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）の糖尿病治療薬SGLT-2阻害剤生産量、成長率、市場シェアを調査している。

二. 消費面では、糖尿病治療薬SGLT-2阻害剤の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーの糖尿病治療薬SGLT-2阻害剤売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の糖尿病治療薬SGLT-2阻害剤市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本糖尿病治療薬SGLT-2阻害剤のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：糖尿病治療薬SGLT-2阻害剤のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： 糖尿病治療薬SGLT-2阻害剤の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおける糖尿病治療薬SGLT-2阻害剤の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章糖尿病治療薬SGLT-2阻害剤メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：糖尿病治療薬SGLT-2阻害剤の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：糖尿病治療薬SGLT-2阻害剤の主要メーカーの概要を提供し、製品の説明と仕様、糖尿病治療薬SGLT-2阻害剤の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：糖尿病治療薬SGLT-2阻害剤の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

The global Antidiabetic SGLT-2 Inhibitor market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Covers:
This report presents an overview of global market for Antidiabetic SGLT-2 Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Antidiabetic SGLT-2 Inhibitor, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Antidiabetic SGLT-2 Inhibitor, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antidiabetic SGLT-2 Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Antidiabetic SGLT-2 Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Antidiabetic SGLT-2 Inhibitor sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals and Novo Nordisk, etc.

Market Segmentation
By Company
    Pfizer
    AstraZeneca
    Johnson & Johnson
    GlaxoSmithKline
    Merck & Co
    Eli Lilly
    Sanofi
    Takeda Pharmaceuticals
    Novo Nordisk
    Servier Laboratories
    Boehringer Ingelheim
    Bristol-Myers Squibb

Segment by Type
    Canagliflozin
    Empagliflozin
    Dapagliflozin
    Other

Segment by Application
    Hospitals
    Clinics
    Other

Segment by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Antidiabetic SGLT-2 Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antidiabetic SGLT-2 Inhibitor sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
    Table 1. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of Canagliflozin
    Table 3. Major Manufacturers of Empagliflozin
    Table 4. Major Manufacturers of Dapagliflozin
    Table 5. Major Manufacturers of Other
    Table 6. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 7. Global Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 8. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2019-2024) & (US$ Million)
    Table 9. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2025-2030) & (US$ Million)
    Table 10. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2019-2024)
    Table 11. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2025-2030)
    Table 12. Global Antidiabetic SGLT-2 Inhibitor Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 13. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2019-2024) & (K Pcs)
    Table 14. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2025-2030) & (K Pcs)
    Table 15. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2019-2024)
    Table 16. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2025-2030)
    Table 17. Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers (2019-2024) & (K Pcs)
    Table 18. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers (2019-2024)
    Table 19. Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 20. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers (2019-2024)
    Table 21. Global Key Players of Antidiabetic SGLT-2 Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
    Table 22. Antidiabetic SGLT-2 Inhibitor Price by Manufacturers 2019-2024 (USD/Pcs)
    Table 23. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 24. Global Antidiabetic SGLT-2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2023)
    Table 25. Global Key Manufacturers of Antidiabetic SGLT-2 Inhibitor, Manufacturing Base Distribution and Headquarters
    Table 26. Global Key Manufacturers of Antidiabetic SGLT-2 Inhibitor, Product Offered and Application
    Table 27. Global Key Manufacturers of Antidiabetic SGLT-2 Inhibitor, Date of Enter into This Industry
    Table 28. Mergers & Acquisitions, Expansion Plans
    Table 29. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2024) & (K Pcs)
    Table 30. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2025-2030) & (K Pcs)
    Table 31. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2019-2024)
    Table 32. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2025-2030)
    Table 33. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2024) & (US$ Million)
    Table 34. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2025-2030) & (US$ Million)
    Table 35. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2019-2024)
    Table 36. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2025-2030)
    Table 37. Antidiabetic SGLT-2 Inhibitor Price by Type (2019-2024) & (USD/Pcs)
    Table 38. Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Type (2025-2030) & (USD/Pcs)
    Table 39. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2024) & (K Pcs)
    Table 40. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2025-2030) & (K Pcs)
    Table 41. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2019-2024)
    Table 42. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2025-2030)
    Table 43. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2024) & (US$ Million)
    Table 44. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2025-2030) & (US$ Million)
    Table 45. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2019-2024)
    Table 46. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2025-2030)
    Table 47. Antidiabetic SGLT-2 Inhibitor Price by Application (2019-2024) & (USD/Pcs)
    Table 48. Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Application (2025-2030) & (USD/Pcs)
    Table 49. US & Canada Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2024) & (K Pcs)
    Table 50. US & Canada Antidiabetic SGLT-2 Inhibitor Sales by Type (2025-2030) & (K Pcs)
    Table 51. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2024) & (US$ Million)
    Table 52. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue by Type (2025-2030) & (US$ Million)
    Table 53. US & Canada Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2024) & (K Pcs)
    Table 54. US & Canada Antidiabetic SGLT-2 Inhibitor Sales by Application (2025-2030) & (K Pcs)
    Table 55. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2024) & (US$ Million)
    Table 56. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue by Application (2025-2030) & (US$ Million)
    Table 57. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 58. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2024) & (US$ Million)
    Table 59. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue by Country (2025-2030) & (US$ Million)
    Table 60. US & Canada Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2024) & (K Pcs)
    Table 61. US & Canada Antidiabetic SGLT-2 Inhibitor Sales by Country (2025-2030) & (K Pcs)
    Table 62. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2024) & (K Pcs)
    Table 63. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2025-2030) & (K Pcs)
    Table 64. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2024) & (US$ Million)
    Table 65. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2025-2030) & (US$ Million)
    Table 66. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2024) & (K Pcs)
    Table 67. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2025-2030) & (K Pcs)
    Table 68. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2024) & (US$ Million)
    Table 69. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2025-2030) & (US$ Million)
    Table 70. Europe Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 71. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2024) & (US$ Million)
    Table 72. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2025-2030) & (US$ Million)
    Table 73. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2024) & (K Pcs)
    Table 74. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2025-2030) & (K Pcs)
    Table 75. China Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2024) & (K Pcs)
    Table 76. China Antidiabetic SGLT-2 Inhibitor Sales by Type (2025-2030) & (K Pcs)
    Table 77. China Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2024) & (US$ Million)
    Table 78. China Antidiabetic SGLT-2 Inhibitor Revenue by Type (2025-2030) & (US$ Million)
    Table 79. China Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2024) & (K Pcs)
    Table 80. China Antidiabetic SGLT-2 Inhibitor Sales by Application (2025-2030) & (K Pcs)
    Table 81. China Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2024) & (US$ Million)
    Table 82. China Antidiabetic SGLT-2 Inhibitor Revenue by Application (2025-2030) & (US$ Million)
    Table 83. Asia Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2024) & (K Pcs)
    Table 84. Asia Antidiabetic SGLT-2 Inhibitor Sales by Type (2025-2030) & (K Pcs)
    Table 85. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2024) & (US$ Million)
    Table 86. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Type (2025-2030) & (US$ Million)
    Table 87. Asia Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2024) & (K Pcs)
    Table 88. Asia Antidiabetic SGLT-2 Inhibitor Sales by Application (2025-2030) & (K Pcs)
    Table 89. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2024) & (US$ Million)
    Table 90. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Application (2025-2030) & (US$ Million)
    Table 91. Asia Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 92. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Region (2019-2024) & (US$ Million)
    Table 93. Asia Antidiabetic SGLT-2 Inhibitor Revenue by Region (2025-2030) & (US$ Million)
    Table 94. Asia Antidiabetic SGLT-2 Inhibitor Sales by Region (2019-2024) & (K Pcs)
    Table 95. Asia Antidiabetic SGLT-2 Inhibitor Sales by Region (2025-2030) & (K Pcs)
    Table 96. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2024) & (K Pcs)
    Table 97. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2025-2030) & (K Pcs)
    Table 98. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2024) & (US$ Million)
    Table 99. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2025-2030) & (US$ Million)
    Table 100. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2024) & (K Pcs)
    Table 101. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2025-2030) & (K Pcs)
    Table 102. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2024) & (US$ Million)
    Table 103. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2025-2030) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 105. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2024) & (US$ Million)
    Table 106. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2025-2030) & (US$ Million)
    Table 107. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2024) & (K Pcs)
    Table 108. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2025-2030) & (K Pcs)
    Table 109. Pfizer Company Information
    Table 110. Pfizer Description and Major Businesses
    Table 111. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 112. Pfizer Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 113. Pfizer Recent Developments
    Table 114. AstraZeneca Company Information
    Table 115. AstraZeneca Description and Major Businesses
    Table 116. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 117. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 118. AstraZeneca Recent Developments
    Table 119. Johnson & Johnson Company Information
    Table 120. Johnson & Johnson Description and Major Businesses
    Table 121. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 122. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 123. Johnson & Johnson Recent Developments
    Table 124. GlaxoSmithKline Company Information
    Table 125. GlaxoSmithKline Description and Major Businesses
    Table 126. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 127. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 128. GlaxoSmithKline Recent Developments
    Table 129. Merck & Co Company Information
    Table 130. Merck & Co Description and Major Businesses
    Table 131. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 132. Merck & Co Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 133. Merck & Co Recent Developments
    Table 134. Eli Lilly Company Information
    Table 135. Eli Lilly Description and Major Businesses
    Table 136. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 137. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 138. Eli Lilly Recent Developments
    Table 139. Sanofi Company Information
    Table 140. Sanofi Description and Major Businesses
    Table 141. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 142. Sanofi Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 143. Sanofi Recent Developments
    Table 144. Takeda Pharmaceuticals Company Information
    Table 145. Takeda Pharmaceuticals Description and Major Businesses
    Table 146. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 147. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 148. Takeda Pharmaceuticals Recent Developments
    Table 149. Novo Nordisk Company Information
    Table 150. Novo Nordisk Description and Major Businesses
    Table 151. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 152. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 153. Novo Nordisk Recent Developments
    Table 154. Servier Laboratories Company Information
    Table 155. Servier Laboratories Description and Major Businesses
    Table 156. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 157. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 158. Servier Laboratories Recent Developments
    Table 159. Boehringer Ingelheim Company Information
    Table 160. Boehringer Ingelheim Description and Major Businesses
    Table 161. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 162. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 163. Boehringer Ingelheim Recent Developments
    Table 164. Bristol-Myers Squibb Company Information
    Table 165. Bristol-Myers Squibb Description and Major Businesses
    Table 166. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
    Table 167. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 168. Bristol-Myers Squibb Recent Developments
    Table 169. Key Raw Materials Lists
    Table 170. Raw Materials Key Suppliers Lists
    Table 171. Antidiabetic SGLT-2 Inhibitor Distributors List
    Table 172. Antidiabetic SGLT-2 Inhibitor Customers List
    Table 173. Antidiabetic SGLT-2 Inhibitor Market Trends
    Table 174. Antidiabetic SGLT-2 Inhibitor Market Drivers
    Table 175. Antidiabetic SGLT-2 Inhibitor Market Challenges
    Table 176. Antidiabetic SGLT-2 Inhibitor Market Restraints
    Table 177. Research Programs/Design for This Report
    Table 178. Key Data Information from Secondary Sources
    Table 179. Key Data Information from Primary Sources
List of Figures
    Figure 1. Antidiabetic SGLT-2 Inhibitor Product Picture
    Figure 2. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Antidiabetic SGLT-2 Inhibitor Market Share by Type in 2023 & 2030
    Figure 4. Canagliflozin Product Picture
    Figure 5. Empagliflozin Product Picture
    Figure 6. Dapagliflozin Product Picture
    Figure 7. Other Product Picture
    Figure 8. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 9. Global Antidiabetic SGLT-2 Inhibitor Market Share by Application in 2023 & 2030
    Figure 10. Hospitals
    Figure 11. Clinics
    Figure 12. Other
    Figure 13. Antidiabetic SGLT-2 Inhibitor Report Years Considered
    Figure 14. Global Antidiabetic SGLT-2 Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Antidiabetic SGLT-2 Inhibitor Revenue 2019-2030 (US$ Million)
    Figure 16. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 17. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2019-2030)
    Figure 18. Global Antidiabetic SGLT-2 Inhibitor Sales 2019-2030 ((K Pcs)
    Figure 19. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2019-2030)
    Figure 20. US & Canada Antidiabetic SGLT-2 Inhibitor Sales YoY (2019-2030) & (K Pcs)
    Figure 21. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue YoY (2019-2030) & (US$ Million)
    Figure 22. Europe Antidiabetic SGLT-2 Inhibitor Sales YoY (2019-2030) & (K Pcs)
    Figure 23. Europe Antidiabetic SGLT-2 Inhibitor Revenue YoY (2019-2030) & (US$ Million)
    Figure 24. China Antidiabetic SGLT-2 Inhibitor Sales YoY (2019-2030) & (K Pcs)
    Figure 25. China Antidiabetic SGLT-2 Inhibitor Revenue YoY (2019-2030) & (US$ Million)
    Figure 26. Asia (excluding China) Antidiabetic SGLT-2 Inhibitor Sales YoY (2019-2030) & (K Pcs)
    Figure 27. Asia (excluding China) Antidiabetic SGLT-2 Inhibitor Revenue YoY (2019-2030) & (US$ Million)
    Figure 28. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales YoY (2019-2030) & (K Pcs)
    Figure 29. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue YoY (2019-2030) & (US$ Million)
    Figure 30. The Antidiabetic SGLT-2 Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 31. The Top 5 and 10 Largest Manufacturers of Antidiabetic SGLT-2 Inhibitor in the World: Market Share by Antidiabetic SGLT-2 Inhibitor Revenue in 2023
    Figure 32. Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 33. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2019-2030)
    Figure 34. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2019-2030)
    Figure 35. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2019-2030)
    Figure 36. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2019-2030)
    Figure 37. US & Canada Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2019-2030)
    Figure 38. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2019-2030)
    Figure 39. US & Canada Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2019-2030)
    Figure 40. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2019-2030)
    Figure 41. US & Canada Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2019-2030)
    Figure 42. US & Canada Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2019-2030)
    Figure 43. U.S. Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 44. Canada Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 45. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2019-2030)
    Figure 46. Europe Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2019-2030)
    Figure 47. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2019-2030)
    Figure 48. Europe Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2019-2030)
    Figure 49. Europe Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2019-2030)
    Figure 50. Europe Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2019-2030)
    Figure 51. Germany Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 52. France Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 53. U.K. Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 54. Italy Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 55. Russia Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 56. China Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2019-2030)
    Figure 57. China Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2019-2030)
    Figure 58. China Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2019-2030)
    Figure 59. China Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2019-2030)
    Figure 60. Asia Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2019-2030)
    Figure 61. Asia Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2019-2030)
    Figure 62. Asia Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2019-2030)
    Figure 63. Asia Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2019-2030)
    Figure 64. Asia Antidiabetic SGLT-2 Inhibitor Revenue Share by Region (2019-2030)
    Figure 65. Asia Antidiabetic SGLT-2 Inhibitor Sales Share by Region (2019-2030)
    Figure 66. Japan Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 67. South Korea Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 68. China Taiwan Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 69. Southeast Asia Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 70. India Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 71. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2019-2030)
    Figure 72. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2019-2030)
    Figure 73. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2019-2030)
    Figure 74. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2019-2030)
    Figure 75. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2019-2030)
    Figure 76. Middle East, Africa and Latin America Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2019-2030)
    Figure 77. Brazil Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 78. Mexico Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 79. Turkey Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 80. Israel Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 81. GCC Countries Antidiabetic SGLT-2 Inhibitor Revenue (2019-2030) & (US$ Million)
    Figure 82. Antidiabetic SGLT-2 Inhibitor Value Chain
    Figure 83. Antidiabetic SGLT-2 Inhibitor Production Process
    Figure 84. Channels of Distribution
    Figure 85. Distributors Profiles
    Figure 86. Bottom-up and Top-down Approaches for This Report
    Figure 87. Data Triangulation
    Figure 88. Key Executives Interviewed